Helixgate

Helixgate

Uncategorized

Bristol Myers’ legacy lift, Biogen’s blue skies and Regeneron’s murky outlook

Investors are still waiting to see whether Bristol Myers and Regeneron’s pipelines will deliver, while Biogen was lifted by better-than-expected results for newer drugs like Leqembi and Skyclarys.

Read More

Published

on

Investors are still waiting to see whether Bristol Myers and Regeneron’s pipelines will deliver, while Biogen was lifted by better-than-expected results for newer drugs like Leqembi and Skyclarys.

Read More

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

Q&A: Seaport CEO and CSO on learning from Karuna and the future of CNS research

Published

on

Seaport Therapeutics began trading as a public company on Friday after executives rang the Nasdaq’s opening bell.

With a team largely made up of Karuna Therapeutics veterans, Seaport is looking to push even further in …

Continue Reading

Uncategorized

Summit’s ‘self-inflicted’ stumble; Esperion’s take-private deal

Summit’s decision to conduct an interim analysis of a closely watched trial backfired. Elsewhere, Axsome got a much-needed label expansion and an FDA committee sided against an AstraZeneca breast cancer medicine.

Read More

Published

on

Summit’s decision to conduct an interim analysis of a closely watched trial backfired. Elsewhere, Axsome got a much-needed label expansion and an FDA committee sided against an AstraZeneca breast cancer medicine.

Read More

Continue Reading

Uncategorized

Samsung Biologics workers begin five-day strike over wage disputes 

Samsung Biologics workers begin five-day strike over wage disputes 

Published

on

After holding a rally in April, Samsung Biologics union workers on Friday started a five-day strike over wage negotiations.

Around 95% of the company’s union members voted on the strike, with the …​ ​Read More

Continue Reading
Advertisement

Trending